Objective: Neonatal gastroesophageal reflux (GER) is primarily due to a transient motility disorder and characterized by a prevalence of weakly acid refluxes. Drug management, where necessary, must set out to reduce the number of refluxes besides correct their acidity. Prokinetics could be of assistance in this respect, though the evidence in favor of their efficacy and safety is still far from sufficient. In this randomized controlled study, the action of domperidone, a prokinetic antidopaminergic drug with little effect on the central nervous system, was evaluated in newborns with symptomatic GER.
Introduction
Gastroesophageal reflux (GER) is one of the most common gastrointestinal (GI) problems in children. 1 Its prevalence in neonates is about 50-60%. 2, 3 Neonatal GER picture is marked by a peculiar pathogenesis, namely inappropriate relaxation of the lower esophageal sphincter (LES) due to immaturity of the GI tract, 4, 5 and by a predominance of weakly acidic episodes (pH 4-7). 6, 7 Multichannel intraluminal impedance (MII) measurement coupled with pH monitoring (MII/pH) has shown that weak acidity is a feature of 50-75% of episodes. 8 It would thus seem advisable to reduce the number of episodes besides correcting their acidity when treating symptomatic newborns.
Prokinetics modulate LES tone, intensify esophageal peristalsis and accelerate gastric emptying, 9 and could thus be of prime importance in the management of neonatal GER. 10 Administration of cisapride and metoclopramide to children, however, might expose to risks of possible side effects on the extrapyramidal system and cardiac conduction. [11] [12] [13] Domperidone, on the other hand, is a prokinetic antidopaminergic that mainly acts outside the central nervous system (CNS) because its molecular weight and low lipid solubility limit its ability to cross the blood-brain barrier.
14 It is thus one of the prokinetics best suited for pediatric treatments. Little, however, is known about its real efficacy and its contraindications, especially in newborns. 15 Aim of the present study was to evaluate the short-term effects of domperidone on GER in symptomatic newborns by means of the simultaneous measurement of impedance and esophageal pH.
Background
Domperidone is a dopaminergic receptor blocker. 16 It activates gastric motility, reduces pyloric tone and increases LES pressure levels. 17 When administered per os, it is rapidly absorbed and reaches its plasma concentration peak after 1 h. The plasma bioavailability of a single oral dose is about 15%. The plasma half-life after a single dose is about 7-9 h in the healthy adult, but much longer in subjects with renal insufficiency. About 30% of an oral dose is excreted in the urine. 18 The appropriate dose in children is from 0.3 to 0.6 mg three times a day. 19 Its estimated incidence of CNS side effects is only 7% compared to 20% for metoclopramide. 20 Even so, extrapyramidal symptoms and oculogyric crises have been described in newborns. 21, 22 As domperidone is prevalently metabolized via the CYP3A4 enzyme system, the concomitant use of drugs that inhibit this enzyme (nitrogenous antifungals, macrolides, nefazodone, human immunodeficiency virus protease inhibitors) may, according to some studies, enhance its plasma levels to the point of toxicity with heart effects, especially lengthening the Q-T interval, with an action similar to that of class III antiarrhythmics. 23 Domperidone may prolong the action potential by blocking the potassium channels, which are sensitive to repolarization, and by increasing the effective refractory period. 24 
Materials and methods

Selection of patients
The study population consisted of term and preterm neonates admitted to the 'Neonatal Pathology Centre' of the Regina Margherita Children's Hospital, Turin, with clinically suspected of gastroesophageal reflux disease (feeding problems, vomiting, irritability, experience of apparent life-threatening events and failure to thrive) who had not responded to conservative therapy.
The exclusion criteria were treatment with drugs known to act on the GI tract or able to interfere with the mechanism of action of domperidone (antacids, anti-H 2 agents, proton pump inhibitors, sympathicolytics, anticholinergics, opioid analgesics and CYP3A inhibitors) and evidence of infection, metabolic or CNS disease.
Study design
The research was conducted in accordance with a prospective randomized controlled study model. The eligible patients were consecutively enrolled in the study. After recruitment they were randomly assigned to the treatment group and the control group. The treatment was randomly allocated by odds on pair from random-number table.
Following an approximately 3-h fasting, all patients were MII/pH monitored for 24 h. A combined impedance/pH meter was connected to an intraesophageal probe. It consisted of a single-use plastic catheter inserted intranasally (with 'containment' and 'consolation' of the neonate) and its distal pH-sensitive tip was positioned 1.5 cm above the LES. The approximate position of the probe was calculated according to Strobel, 25 checked radiologically and corrected if necessary.
To obtain comparable MII/pH measurements the recording conditions were arbitrarily standardized concerning feed volume and body position.
The patients received 25 ml/kg per meal maternal or formula milk from a feeding bottle every 4 h. They were kept supine on a surface inclined at 301 and continuously subjected to cardiooximetric monitoring.
Note was taken of significant events likely to influence the tracings, such as temporary changes of position during the nursing operations, drug administration times, crying periods or any interruptions of the recording.
Baseline values were established during the first 8 h. The treatment group then received doses of 0.3 mg per kg domperidone per os with their 8 h meal and then with their 16 h meal.
The research protocol was approved by the local ethics committee. Written consent was obtained from the parents.
Technique
The effects of domperidone on GER were assessed by combined MII/pH monitoring, a technique that detects reflux episodes as changes in impedance recorded between pairs of electrodes located along a catheter in the esophageal lumen, and determines their pH by means of a pH-sensitive antinomy electrode.
Single-use combined MII/pH catheters with a pH-sensitive antimony electrode and seven integrated impedance electrodes were used. Impedance was measured bipolarly among paired electrodes that form six impedance channels. For signal processing and recording, the electrodes were connected to impedance-voltage transducers and a recording device outside the body (Sleuth System; Sandhill Scientific Inc., Highlands Ranch, CO, USA) by thin wires that run inside the plastic probe. The distance among the electrodes was 1.5 cm. The total measuring segment extended from 1.5 cm above the LES (channel 1, distal) to the pharynx (channels 4-6, proximals, depending on the neonatal length) with the pH sensor at channel 1.
Impedance decreases during the passage of a high-conductivity bolus, such as saliva, milk or GI secretions, and increases during the passage of air. MII tracings clearly illustrate the patterns of antegrade and retrograde bolus movement and their duration and proximal extent. 26 A GER episode was defined as a decrease of impedance starting in the most distal channel, extending proximally over two channels and followed by an increase in impedance to baseline values. 27 Combined MII/pH identified GER episodes and illustrated their duration, proximal extent and pH. The duration of an episode was defined as the time, in seconds, between its onset at the 50% drop in impedance from baseline relative to nadir and bolus exit at the 50% recovery point from nadir to baseline recorded at channel 1. Its proximal extent was defined as the number of channels sequentially involved in the temporary impedance decrease. The pH of an episode was the nadir esophageal pH recorded during the episode.
Combined MII/pH also detected GER episodes that pH measurements alone would not have revealed owing to their short duration (<15 s), or to gastric hypoacidity (pHX4) due to neutralization caused by the ingestion of food. 28, 29 It thus allows the sequential recording of reflux episodes occurring when the intraesophageal pH is stable. 30 
Data analysis
The MII/pH tracings were examined by a single operator. Segments with artifacts or interruptions of the signal and those corresponding to nursing operations (changing of napkins, bathing and so on) and the feeding time were discarded.
Three consecutive 8-h observation periods were identified for each MII/pH tracing to create one baseline period (P 0 ) from the first to the eighth hour and two treatment periods (P 1 , P 2 ) from the eighth to the sixteenth and the sixteenth to the twentieth hour.
The following end points were obtained for the three 8-h periods examined on each patient's tracing:
Reflux frequency: number of refluxes per hour Mean reflux duration: in seconds Mean reflux level: expressed as the number of channels Mean reflux pH: mean of the minimum pH value during each reflux For the statistical analysis each treated patient was matched with the nearest control considering postconceptional age at the day of enrollment. Periods P 1 and P 2 were compared with P 0 for both groups. Treatment group was then compared with control group period by period. Statistical analysis was performed by using the paired t-test and the Stat 5.5 software (Statsoft Inc., Tulsa, OK, USA). Significance was indicated by a value of P<0.05.
Results
Twenty-six neonates (14 boys, 12 girls) were studied. There were no significant differences in the general characteristics of the two groups ( Table 1) .
The tracing times amounted to 613.3 h. Elimination of the segments with artifacts, interruptions and so on corresponding to 49.3 h (8% of the total) resulted in the examination and comparison of tracings for 564 h: 287.9 for the treatment group and 276.2 for the control group.
No ECG and oximetric alterations, nor other side effects attributable to domperidone were noted.
The treatment group displayed significant increase in reflux frequency during periods P 1 þ P 2 compared with P 0 (4.06 ± 1.16 vs 2.8 ± 1.42; P ¼ 0.001), and a decrease in duration (16.68±4.49 vs 20.18±7.83; P ¼ 0.043), whereas there were MII/pH was interrupted in one patient of the treatment group prior to the end of the study. This subject and the corresponding control were thus discarded when comparisons were made with the P 2 period. Reflux data for the baseline and treatment periods are illustrated in Figure 1 .
Discussion
It has recently been demonstrated that prokinetics are widely used in neonatal intensive care units for the treatment of GER. 31, 32 Following the banning of cisapride, most countries have turned to domperidone for this purpose, despite the reports of its possible side effects and the fact that its efficacy in children has been the subject of only four heterogeneous randomized controlled trials, none of which included neonates. 19, [33] [34] [35] It is freely marketed and widely used by Italian pediatricians to treat GER, even though it is not licensed for this use.
The present clinical trial thus provides the first objective assessment of the effects of domperidone on neonatal GER in a homogeneous population by means of a technique that ensures extremely sensitive and specific characterization of reflux episodes.
The study was confined to 24 h because this is the standard recording period for the MII/pH technique, as well as for the obvious need to limit risks and discomfort when dealing with such young patients. The pharmacokinetics of domperidone, however, resulted in the production of measurable effects on the gastroesophageal tract over the course of the 16-h treatment period. Prolonged administration and long-term physiological effects and side effects, of course, require further investigation.
Our results, in fact, show that domperidone significantly influenced reflux frequency and duration, but had no effect on its mean proximal extent and pH value.
The reduction in reflux duration shows that domperidone acts on esophageal clearance. Other workers, in fact, have suggested that prokinetics increase gastroesophageal motility and facilitate emptying of the stomach by improving peristalsis and reducing pyloric tone. 15 This beneficial effect, however, was significant after the first drug administration only and was accompanied by an unexpected increase in reflux frequency. Actually there are insufficient safety data to explain these results. In our opinion, this increase in frequency may express a specific feature of the pathogenesis of GER in the newborn. The action of a prokinetic on the dopaminergic receptors of the gastric wall may thus have a different effect in newborns compared to with older patients.
A physiopathological study of the relations between GER and gastric activity in the newborn has shown that a highly variable gastric emptying rate may lead to increased reflux frequency, as episodes are more frequent during slow emptying, that is, when peristalsis is ineffective. 36 Domperidone may thus augment the negative effect of the gastric motor incoordination due to immaturity by increasing the variability of the emptying rate and promoting refluxes.
In conclusion therefore, our results cast doubt on the efficacy of domperidone in the management of neonatal GER and suggest that its use in this setting should be discouraged.
